Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00491530 · ClinicalTrials.gov registry record · Phase 3
A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 310
- Enrollment target
NCT00491530 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 310 participants.
The verdict
NCT00491530, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 310 participants
- Enrollment target
Study Summary
The objective of the study is to assess the continued safety of the daily coadministration of ABT-335 in combination with rosuvastatin calcium, simvastatin or atorvastatin calcium.
Interventions
- DRUG ABT-335
- DRUG simvastatin
- DRUG rosuvastatin calcium
- DRUG atorvastatin calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00491530
The ClinicalTrials.gov registry entry for NCT00491530 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ABT-335 is the first listed.
NCT00491530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00491530 about?
NCT00491530 is a clinical study titled "A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia". The objective of the study is to assess the continued safety of the daily coadministration of ABT-335 in combination with rosuvastatin calcium, simvastatin or atorvastatin calcium.
What is the current status of trial NCT00491530?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 310 participants. The study started on 2007-06. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00491530?
The interventions under investigation include: ABT-335 (DRUG), simvastatin (DRUG), rosuvastatin calcium (DRUG), atorvastatin calcium (DRUG).
Who is sponsoring clinical trial NCT00491530?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.